Læknablaðið - 01.09.2014, Side 18

450 LÆKNAblaðið 2014/100
Heimildir
1. Organization WH. Management of substance abuse 2013.
who.int/substance_abuse/facts/cannabis/en/ - apríl
2014.
2. Vímuefnaneysla unglinga í efstu bekkjum grunnskóla á
Íslandi: Þróun frá 1997 til 2012: Rannsóknir og greining,
Háskólinn í Reykjavík 2012.
3. Ashton CH. Pharmacology and effects of cannabis: a brief
review. Br J Psychiatry 2001; 178: 101-6.
4. Andreasson S, Allebeck P, Engstrom A, Rydberg U.
Cannabis and schizophrenia. A longitudinal study of
Swedish conscripts. Lancet 1987; 2: 1483-6.
5. Degenhardt L, Hall W. The association between psychosis
and problematical drug use among Australian adults:
findings from the National Survey of Mental Health and
Well-Being. Psychol Med 2001; 31: 659-68.
6. Kessler RC, Crum RM, Warner LA, Nelson CB,
Schulenberg J, Anthony JC. Lifetime co-occurrence of
DSM-III-R alcohol abuse and dependence with other
psychiatric disorders in the National Comorbidity Survey.
Arch Gen Psychiatry 1997; 54: 313-21.
7. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd
LL, et al. Comorbidity of mental disorders with alcohol
and other drug abuse. Results from the Epidemiologic
Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.
8. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in
users and nonusers of cannabis. A longitudinal study in
Stockholm County. Acta Psychiatr Scand 1989; 79: 505-10.
9. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis
G. Self reported cannabis use as a risk factor for schizop-
hrenia in Swedish conscripts of 1969: historical cohort
study. BMJ 2002; 325: 1199.
10. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson
T, Andreasson S, Allebeck P. Cannabis, schizophrenia and
other non-affective psychoses: 35 years of follow-up of a
population-based cohort. Psychol Med 2012; 42: 1321-8.
11. Eaton WW, Regier DA, Locke BZ, Taube CA. The
Epidemiologic Catchment Area Program of the National
Institute of Mental Health. Public Health Rep 1981; 96:
319-25.
12. Tien AY, Anthony JC. Epidemiological analysis of alcohol
and drug use as risk factors for psychotic experiences. J
Nerv Ment Dis 1990; 178: 473-80.
13. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux
H. Cannabis use and psychosis: a longitudinal population-
based study. Am J Epidemiol 2002; 156: 319-27.
14. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A,
Moffitt TE. Cannabis use in adolescence and risk for adult
psychosis: longitudinal prospective study. BMJ 2002; 325:
1212-3.
15. Yung AR, McGorry PD, Francey SM, Nelson B, Baker K,
Phillips LJ, et al. PACE: a specialised service for young
people at risk of psychotic disorders. Med J Aust 2007; 187:
S43-6.
16. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S,
McGorry PD. Cannabis use is not associated with the
development of psychosis in an ‚ultra‘ high-risk group.
Aust N Z J Psychiatry 2002; 36: 800-6.
17. Fergusson DM, Horwood LJ, Swain-Campbell NR.
Cannabis dependence and psychotic symptoms in young
people. Psychol Med 2003; 33: 15-21.
18. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal
linkages between cannabis use and psychotic symptoms.
Addiction 2005; 100: 354-66.
19. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R,
Wittchen HU, et al. Prospective cohort study of cannabis
use, predisposition for psychosis, and psychotic symp-
toms in young people. BMJ 2005; 330: 11.
20. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M,
Henquet C. Continued cannabis use and risk of incidence
and persistence of psychotic symptoms: 10 year follow-up
cohort study. BMJ 2011; 342: d738.
21. Singleton N, Bumpstead R, O‘Brien M, Lee A, Meltzer
H. Psychiatric morbidity among adults living in private
households, 2000 (Reprinted from Psychiatric morbidity
among adults living in private households, 2000:
Summary report,, 2001). Int Rev Psychiatry 2003; 15: 65-73.
22. Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer
H, Lewis G. Self-reported psychotic symptoms in the
general population: results from the longitudinal study
of the British National Psychiatric Morbidity Survey. Br J
Psychiatry 2006; 188: 519-26.
23. Najman JM, Bor W, O‘Callaghan M, Williams GM, Aird R,
Shuttlewood G. Cohort Profile: The Mater-University of
Queensland Study of Pregnancy (MUSP). Int J Epidemiol
2005; 34: 992-7.
24. McGrath J, Welham J, Scott J, Varghese D, Degenhardt
L, Hayatbakhsh MR, et al. Association between cannabis
use and psychosis-related outcomes using sibling pair
analysis in a cohort of young adults. Arch Gen Psychiatry
2010; 67: 440-7.
25. Rolfe M, Tang CM, Sabally S, Todd JE, Sam EB, Hatib N‘Jie
AB. Psychosis and cannabis abuse in The Gambia. A case-
control study. Br J Psychiatry 1993; 163: 798-801.
26. Grech A, Takei N, Murray RM. Comparison of cannabis
use in psychotic patients and controls in London and
Malta. Schizophr Res 1998; 29: 22.
27. Degenhardt L, Hall W. The association between psychosis
and problematical drug use among Australian adults:
findings from the National Survey of Mental Health and
Well-Being. Psychol Med 2001; 31: 659-68.
28. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R,
Johnstone EC. Genetic liability, illicit drug use, life stress
and psychotic symptoms: preliminary findings from the
Edinburgh study of people at high risk for schizophrenia.
Soc Psychiatry Psychiatr Epidemiol 2001; 36: 338-42.
29. Farrell M, Boys A, Bebbington P, Brugha T, Coid J, Jenkins
R, et al. Psychosis and drug dependence: results from a
national survey of prisoners. Br J Psychiatry 2002; 181:
393-8.
30. Agosti V, Nunes E, Levin F. Rates of psychiatric
comorbidity among U.S. residents with lifetime cannabis
dependence. Am J Drug Alcohol Abuse 2002; 28: 643-52.
31. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis
CN, Van Os J. Early adolescent cannabis exposure and
positive and negative dimensions of psychosis. Addiction
2004; 99: 1333-41.
32. Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-
Bruce H, Miller R, et al. Are cannabis use disorders
associated with an earlier age at onset of psychosis? A
study in first episode schizophrenia. Schizophr Res 2010;
120: 101-7.
33. Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F,
Becker H, de Haan L, et al. Cannabis use and age at onset
of symptoms in subjects at clinical high risk for psychosis.
Acta Psychiatr Scand 2012; 125: 45-53.

34. Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Acute
effects of drug abuse in schizophrenic patients: clinical
observations and patients‘ self-reports. Schizophr Bull
1990; 16: 69-79.
35. Peralta V, Cuesta MJ. Influence of cannabis abuse on
schizophrenic psychopathology. Acta Psychiatr Scand
1992; 85: 127-30.
36. Meier MH, Caspi A, Ambler A, Harrington H, Houts R,
Keefe RSE, et al. Persistent cannabis users show neurop-
sychological decline from childhood to midlife. Proc Natl
Acad Sci U S A 2012; 109: E2657-E64.
37. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R,
Miller M, et al. Cognitive functioning of long-term heavy
cannabis users seeking treatment. JAMA 2002; 287: 1123-
31.
38. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors
in the human brain: A detailed anatomical and quantita-
tive autoradiographic study in the fetal, neonatal and
adult human brain. Neuroscience 1997; 77: 299-318.
39. Laviolette SR, Grace AA. The roles of cannabinoid and
dopamine receptor systems in neural emotional learning
circuits: implications for schizophrenia and addiction. Cell
Mol Life Sci 2006; 63: 1597-613.
40. Kirkbride J. The risk of substance-induced psychosis
converting to schizophrenia varies with substance used
and patient age. Evid Based Ment Health 2013; 16: 65.
41. Johns LC, van Os J. The continuity of psychotic experien-
ces in the general population. Clin Psychol Rev 2001; 21:
1125-41.
42. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P,
Krabbendam L. A systematic review and meta-analysis of
the psychosis continuum: evidence for a psychosis prone-
ness-persistence-impairment model of psychotic disorder.
Psychol Med 2009; 39: 179-95.
43. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR,
Jones PB, Burke M, et al. Cannabis use and risk of psycho-
tic or affective mental health outcomes: a systematic
review. Lancet 2007; 370: 319-28.
44. Large M, Sharma S, Compton MT, Slade T, Nielssen O.
Cannabis Use and Earlier Onset of Psychosis. Arch Gen
Psychiatry 2011; 68: 555-61.
45. Degenhardt L, Hall W, Lynskey M. Testing hypotheses
about the relationship between cannabis use and psyc-
hosis. Drug Alcohol Depend 2003; 71: 37-48.
46. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence
of psychotic disorder and community level of psycho-
tic symptoms: an urban-rural comparison. Arch Gen
Psychiatry 2001; 58: 663-8.
47. Verdoux H, Maurice-Tison S, Gay B, Van Os J, Salamon R,
Bourgeois ML. A survey of delusional ideation in primary-
care patients. Psychol Med 1998; 28: 127-34.
48. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink
RJ. Strong increase in total delta-THC in cannabis prep-
arations sold in Dutch coffee shops. Addict Biol 2005; 10:
171-80.
49. Vindenes V, Strand DH, Kristoffersen L, Boix F, Morland J.
Has the intake of THC by cannabis users changed over the
last decade? Evidence of increased exposure by analysis of
blood THC concentrations in impaired drivers. Forensic
Sci Int 2013; 226: 197-201.
50. Volkov ND, Baler RD, Compton WN, Weiss SRB. Adverse
health effects of marijuana use. N Engl J Med 2014; 370:
2219-27.
Y F I R L I T